肺癌主动靶向给药的研究进展与评价  

Research Progress and Evaluation of Active Targeting Drug Delivery for Lung Cancer

作　　者：陈彦刚[1] 朱宏[1] 

机构地区：[1]南京工业大学材料科学与工程学院纳米生物技术研究所,南京210009

出　　处：《中国实验方剂学杂志》2013年第12期360-366,共7页Chinese Journal of Experimental Traditional Medical Formulae

摘　　要：外科诊疗技术及化疗、放疗等作为肺癌的主要治疗手段,虽然对肺癌的治疗起到一定效果,但对患者长期生存的改善程度较小。主动靶向治疗技术因其安全、高效、低毒的治疗效果而成为当前肺癌研究的热点之一。该文介绍了目前主动靶向治疗肺癌过程中的各类靶分子及靶向机制,对靶分子的活化方式和偶联机制进行了总结,并阐述了当前肺靶向制剂的研究进展,最后对其临床应用进行了展望。尽管主动靶向给药系统仍有许多关键技术需要解决,但在靶向给药方面已显示出无可比拟的优越性,必将会有更多的研究和更广阔的应用前景。The main treatments of lung cancer are surgical treatment techniques,chemotherapy and radiotherapy,which play a certain effect,but a smaller degree of improvement in patients with long-term survival.Targeted therapy technology,because of its safety,availabilityand low toxicity,has become one of the hotspots of the current lung cancer research.This article describes various types of target molecules in the active targeted therapy of lung cancer process and targeting mechanism,summarizes the targeting molecular’s activation method and coupling mechanism,and also expounds the progress of targeting preparation at present.Finally,the clinical application prospect.

关 键 词：肺癌 靶向治疗 受体 抗原 靶向制剂 

分 类 号：R283[医药卫生—中药学]